Introduction Prostate specific membrane antigen (PSMA), highly expressed in metastatic
castration-resistant prostate cancer (mCRPC), is an established therapeutic target …

Purpose Treatment of late-stage prostate cancer by targeted radiotherapeutics such as 131 I-
MIP-1095 and 177 Lu-PSMA-617 has shown encouraging early results. Lu-177 is preferred …

Prostate-specific membrane antigen (PSMA) is an excellent target for imaging and
radionuclide therapy of prostate cancer. Recently,[177Lu] Lu-PSMA-617 (Pluvicto) was …

Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide.
Prostate-specific membrane antigen (PSMA) is a surface molecule specifically expressed by …

Purpose Prostate-specific membrane antigen (PSMA) is a promising target for diagnosis and
radioligand therapy (RLT) of prostate cancer. Two novel PSMA-targeting radionuclide …

On the basis of the high and consistent expression of prostate-specific membrane antigen
(PSMA) in metastatic prostate cancer (PC), the goal of this study was the development …

Purpose PSMA (prostate-specific membrane antigen) is highly expressed on prostate
cancer (PrCa) cells and extensively used as a homing target for PrCa treatment. Most …

The use of an albumin binder has been shown to improve tumor uptake of prostate-specific
membrane antigen (PSMA)–targeting radiotherapeutic agents. The aim of this study was to …

Prostate-specific membrane antigen (PSMA)-targeted radiolabeled agents have been
developed to diagnose and treat prostate cancer. In this study, we developed a novel 68Ga …

Prostate-specific membrane antigen (PSMA) represents a promising target for PSMA-
overexpressing diseases, especially prostate cancer-a common type of cancer among men …